BofA’s Hartnett says concentrated U.S. stock returns are likely to persist
BOCA RATON - INmune Bio Inc. (NASDAQ:INMB), a clinical-stage biotech company with a market capitalization of $144.6 million and shares trading at $6.28, will host a conference call on Monday, June 30 at 8:00 AM EDT to present top line data from its Phase 2 MINDFuL clinical trial in early Alzheimer’s Disease, according to a press release statement. The stock has shown remarkable momentum, gaining nearly 58% year-to-date, according to InvestingPro data.
The MINDFuL trial is an international, blinded, randomized study evaluating the company’s XPro treatment in patients with early Alzheimer’s Disease who exhibit biomarkers of elevated neuroinflammation. Participants in the trial received either XPro or placebo in a 2:1 ratio for six months. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 2.64, providing adequate resources for its clinical programs.
The conference call will be accessible via phone at +1-800-267-6316 for U.S. callers or +1-203-518-9783 for international participants using the conference ID "INMUNE." A webcast option will also be available, with a transcript to follow approximately 24 hours after the call.
XPro is a next-generation inhibitor of tumor necrosis factor that neutralizes soluble TNF without affecting trans-membrane TNF or TNF receptors. The drug is administered as a once-weekly subcutaneous injection.
The MINDFuL trial (NCT05318976) enrolled patients with mild cognitive impairment and mild Alzheimer’s Disease who demonstrated at least one of four biomarkers of inflammation: elevated CRP, HgbA1c, ESR, or presence of the ApoE4 allele. The primary cognitive endpoints of the study are EMACC and CDR assessments.
INmune Bio is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat various diseases, including neurological conditions, cancer, and inflammatory disorders. Analysts maintain a bullish outlook on the company, with price targets ranging from $20 to $30 per share. For deeper insights into INMB’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro, which offers exclusive ProTips and detailed financial metrics for over 1,400 US stocks.
In other recent news, INmune Bio Inc. reported a narrowed net loss of $9.7 million for the first quarter of 2025, improving from an $11 million loss in the same period last year. The company’s earnings per share (EPS) surpassed expectations, coming in at -$0.43 compared to the forecasted -$0.49. Lucid Capital Markets initiated a Buy rating for INmune Bio, setting a price target of $25, reflecting optimism about the company’s development of XPro, a treatment targeting neuroinflammation in Alzheimer’s disease. Additionally, a study presented at the Keystone Symposia’s Neurodegeneration conference suggested that XPro might reduce Alzheimer’s-like pathology in mice following traumatic brain injury. The ongoing MINDFul trial, a Phase 2 study, is evaluating XPro’s safety and efficacy in early Alzheimer’s patients, with results expected in June. The company maintains a strong cash position of $19.3 million, projected to support operations through the third quarter of 2025. INmune Bio also plans to file a Biologics License Application for its RDEB treatment, Cordstrom, in 2026. These developments underscore the company’s focus on innovative treatments for Alzheimer’s and other conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.